Mobile
Recherche simple
Recherche avancée
Recherche multicritère
Qui sommes-nous ?
Connexion
Inscription
French
English
Kusajili – Centralise les essais cliniques mondiaux
Résultat
de votre recherche par promoteur : Gloucester Pharmaceuticals Inc
Femme et Homme Max 99 ans
Gloucester Pharmaceuticals Inc
MAJ Il y a 5 ans
A single agent Phase II study of depsipeptide (FK228) in the treatment of Cutaneous T-cell lymphoma
To confirm the efficacy of FK228, depsipeptide, as reported in the Phase I and early Phase II studies, in patients with CTCL who are no longer controlled on skin-directed therapy and who have had at l...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
Essai clos aux inclusions
Plus d'informations
Femme et Homme Max 99 ans
Gloucester Pharmaceuticals Inc
MAJ Il y a 5 ans
An exploratory Phase II, multicenter, open-label trial evaluating the activity and tolerability of of FK228 in androgen independent metastatic prostate cancer patients with a rising PSA
The primary objective of this trial is to evaluate the activity of FK228 in patients with metastatic prostate cancer who have developed a rising PSA while undergoing hormonal therapy. Activity will b...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gloucester Pharmaceuticals Inc
MAJ Il y a 5 ans
A MULTICENTER, OPEN-LABEL CONTINUATION TRIAL EVALUATING THE TOLERABILITY AND ACTIVITY OF DEPSIPEPTIDE (FK228) IN PATIENTS THAT HAVE COMPLETED A PRIOR CLINICAL STUDY WITH DEPSIPEPTIDE
The primary objective of this trial is to evaluate the safety and tolerability of extended treatment with depsipeptide in patients who have at least demonstrated stable disease on a prior Gloucester-s...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations
Femme et Homme Max 99 ans
Gloucester Pharmaceuticals Inc
MAJ Il y a 5 ans
A PHASE II, MULTICENTER, OPEN-LABEL TRIAL EVALUATING THE ACTIVITY AND TOLERABILITY OF ROMIDEPSIN (DEPSIPEPTIDE, FK228) IN PROGRESSIVE OR RELAPSED PERIPHERAL T-CELL LYMPHOMA FOLLOWING PRIOR SYSTEMIC THERAPY
The primary objective of this trial is to evaluate the activity of romidepsin in patients with progressive or relapsed PTCL following prior systemic therapy. The primary efficacy parameter is the rat...
Pays
Aucun
Organes
Aucun
Spécialités
Aucune
unknown
Plus d'informations